Literature DB >> 15141291

Looking at subgroups in an inhomogeneous population does not make these subgroups more homogeneous.

Jean Carlet.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15141291     DOI： 10.1007/s00134-004-2324-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Drotrecogin alfa (activated) administration: too many subgroups.

Authors:  J Carlet
Journal:  Crit Care Med       Date:  2003-10       Impact factor: 7.598

2.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 3.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

5.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Authors:  C Brun-Buisson; F Doyon; J Carlet; P Dellamonica; F Gouin; A Lepoutre; J C Mercier; G Offenstadt; B Régnier
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272
  5 in total
  1 in total

1.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.